Trial Profile
A Phase IB/II to Evaluate Efficacy and Safety of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Dalpiciclib (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 19 Nov 2023 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results (data cutoff date was Sep. 20, 2021; n=104)presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2021 Planned End Date changed from 30 Jun 2021 to 30 Jun 2022.